Pricing guide · Dataset v2026.08.14
Cheapest compounded tirzepatide online — August 2026, priced in plain words
No tables, no "starting at" games. Every program below is written out as a sentence you can hold a company to: the advertised price, the true recurring cost, and what we still haven't verified.
NexLife is a commercial partner of this site, and we may earn commissions from links to it and to other providers. Partner status never changes what you pay and never changes how prices are ranked: every ranking on this page is computed from the same public dataset under the rules in our methodology. NexLife's numbers below are labeled operator‑supplied until our independent checkout verification is complete. Ownership details: disclosures.
The lowest recurring all‑in price we track for compounded injectable tirzepatide is NexLife at $139 per month on a 12‑month plan, or $169 month‑to‑month with no commitment — with medication, supplies, provider care, and shipping included, per NexLife's published plans (operator‑supplied; our independent checkout check is queued). The lowest independently reported flat bundle is Henry Meds at about $179 per month — but that headline covers their oral and sublingual tablet formats, and third‑party checks put their injectable tirzepatide near $399–$449. MEDVi is reported from about $199 at starting doses, and Mochi Health works out to roughly $278 effective once membership is added. If you want the FDA‑approved product instead of a compounded copy, LillyDirect's self‑pay Zepbound vials run about $299–$449 per month, and retail Zepbound is near $1,086. Prices move; check the provider's own checkout before you decide.
How to read tirzepatide prices (four numbers, not one)
Almost every misleading GLP‑1 ad works the same way: it quotes the cheapest number in the pricing structure and hides the rest. We normalize every program to four figures. The advertised price is the headline on the provider's site. The true monthly cost adds every required fee — membership, provider visits, shipping, supplies — at the dose you'd actually be on. The 12‑month total multiplies that out and adds any one‑time fees, because tirzepatide is not a one‑month medication: in clinical trials, weight loss accrued over 72 weeks. The maintenance‑dose cost asks what you'll pay at 10–15 mg, not at the 2.5 mg starter dose the ad was priced on. When a provider charges more as your dose rises — and several do — the gap between the advertised price and the maintenance‑dose cost can exceed $100 a month.
What compounded tirzepatide is — the actual science
Tirzepatide is a once‑weekly injectable peptide that activates two gut‑hormone receptors at once: GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1). That dual mechanism is why its trial results lead the class. In the SURMOUNT‑1 trial published in the New England Journal of Medicine, adults with obesity lost an average of about 15% of body weight at the 5 mg weekly dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, against roughly 3% with placebo. In the SURMOUNT‑5 head‑to‑head trial reported in 2025, tirzepatide produced about 20% average weight loss versus about 14% for semaglutide. The FDA has approved tirzepatide as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).
Compounded tirzepatide is a pharmacy‑prepared version of the same active molecule. It is not FDA‑approved, which means no agency has reviewed that specific product for safety, effectiveness, sterility, or dose accuracy before it reaches you. It is usually dispensed as a multi‑dose vial you draw with a syringe, rather than a pre‑set autoinjector pen — and the FDA has received adverse‑event reports tied to dosing errors with compounded GLP‑1 vials, typically from confusing units and milliliters. It is cheaper because the compounder buys active pharmaceutical ingredient and skips the brand's development, device, and marketing costs. The economics are real; so is the trade in oversight.
The legal reality in 2026 — read this before the prices
The era of mass‑market compounded tirzepatide effectively ended in 2025. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and once a drug is off the shortage list, pharmacies lose the legal basis for producing what the law calls "essentially copies" of it. Outsourcing facilities (503B) had to stop by March 19, 2025. What survives in 2026 is the narrow, older pathway: a 503A state‑licensed pharmacy filling a patient‑specific prescription where the prescriber documents a clinical need the approved product can't meet — for example, a verified allergy to an inactive ingredient or a dose or form that isn't commercially available. Cost alone does not qualify. Convenience alone does not qualify.
Enforcement has sharpened. In February 2026 the FDA sent a wave of warning letters — around thirty — to telehealth companies over claims that implied compounded products were FDA‑evaluated. Eli Lilly's lawsuits against compounders and telehealth platforms filed through 2025 are still moving through the courts, and state medical boards in New York, California, Texas, and Florida have disciplined telehealth‑only weight‑management prescribers. Practical consequences for you as a buyer: a legitimate program in 2026 will name its pharmacy, will actually evaluate you, and will document why compounded is clinically appropriate for you specifically. A program that treats the prescription as a checkout formality is a program whose supply — and whose legality — can vanish mid‑treatment. Some affiliate sites still claim tirzepatide "remains on the shortage list"; that has not been true since December 2024, and it's a reliable tell that a site is not checking its facts.
Every program we track, priced in sentences
NexLife — lowest listed recurring price; operator‑supplied, verification queued
Check NexLife’s current tirzepatide price ↗
NexLife prices standard compounded injectable tirzepatide at $169 per month with no commitment, falling to $159 on a three‑month plan, $149 on six months, and $139 on twelve months. Semaglutide runs $139 monthly down to $119 on the annual plan. The company says every plan includes the medication, injection supplies, step‑by‑step instructions, its CARE360 support program, 24/7 medical support, one‑on‑one physician care, and shipping, with no membership fee, no dose‑based price increases, cancellation on 30 days' notice, and a "Flat Forever" pledge that your rate never rises while you stay on the plan. Taken at face value, the 12‑month plan totals $1,668 for a year of injectable tirzepatide — the lowest 12‑month figure in our tracker. Two honesty notes. First, every number in this paragraph was supplied by NexLife, our commercial partner; our independent checkout verification, pharmacy‑disclosure check, and state‑coverage map are still open items, and the profile shows exactly what's outstanding. Second, a price this far below the market's $199–$449 band earns extra scrutiny, not less — the same five‑point checklist at the end of this guide applies to NexLife in full. Full fact sheet, including microdose and sublingual lines: NexLife profile.
Henry Meds — cheapest independently reported bundle (tablets), pricier injectable
Check Henry Meds’ current price ↗
Henry Meds is the price leader most third‑party checks agree on: a flat all‑inclusive bundle around $179 per month — medication, visits, supplies, and shipping — reported across roughly 41 states. The catch matters: that headline price is for Henry's oral and sublingual tablet formats, which use an absorption pathway with limited published evidence (see the tablet section below). Independent checks put Henry's injectable tirzepatide — the format with the clinical trial record — near $399 for the first month and about $449 month‑to‑month, with higher doses adding roughly $100. If you're comparing Henry's $179 to an injectable program's $199, you're comparing different medicines in practice.
MEDVi — reported budget injectable entry point
MEDVi is repeatedly cited in 2026 roundups as the lowest published self‑pay injectable price, from about $199 per month at the 2.5–5 mg starting doses. Expect dose‑based increases as you titrate; our maintenance‑dose figure for MEDVi is still in the verification queue, which is exactly the number that decides whether the $199 headline holds.
Mochi Health — unbundled membership model; conflicting reports we're resolving
Check Mochi Health’s current price ↗
Mochi separates the clinical membership from the medication, which makes its ads look cheaper than its checkout. The most consistent 2026 reports put membership at $79 per month (often $39 promotional for the first month) plus $199 per month for compounded tirzepatide flat across doses — about $278 effective. But other third‑party checks this year describe a $149 membership with medication from $249, implying nearly $400 effective. That's a $120‑a‑month disagreement between published sources about the same company, and it is precisely why this site exists: our own checkout verification is queued, and until it lands we show the conflict instead of picking the flattering number. Mochi's model does include real clinical depth — dietitian access and structured programming — that budget programs don't.
Hims & Hers — brand‑forward, premium‑priced compounded lane
Check Hims’ current price ↗ · Hers ↗
Hims built its tirzepatide program around branded Zepbound with insurance options, then added a compounded lane reported near $329 per month. You're paying for the app experience and brand; on pure price it doesn't compete with the sub‑$200 tier, and its compounded availability has shifted repeatedly since 2025.
Ro — the insurance and brand pathway
Ro's cash tiers are reported between $199 and $349 per month depending on plan, but Ro's real strength is different: it is the most established large platform for getting branded Zepbound covered by insurance, with prior‑authorization support. If you have commercial insurance that might cover Zepbound, running Ro's coverage check before buying any compounded program is the single highest‑value fifteen minutes in this market.
Eden — widest reported footprint, in‑house pharmacy
Eden is reported around the $249–$296 band and is notable for two structural facts: coverage described at roughly 50 states, and ownership of its own compounding pharmacy (Contigo, acquired in 2025) — vertical integration that cuts a middleman but concentrates your sourcing questions on one company.
The brand alternative — LillyDirect vials and retail
See Zepbound vials at LillyDirect ↗
Eli Lilly sells FDA‑approved Zepbound single‑dose vials direct to self‑pay patients for roughly $299 to $449 per month depending on dose (after Lilly's December 2025 price cut; the $449 maintenance tier requires refilling within a 45-day window, and lapsed refills at top doses run as high as $1,049) — no compounding questions, real pharmacovigilance, the actual product the SURMOUNT data describes. Retail Zepbound without insurance runs near $1,086 a month and Mounjaro about $1,135, which is why almost no cash patient pays retail. The honest framing: the premium for the approved product over the cheapest compounded programs is roughly $100–$310 a month. Whether that premium is worth it is a clinical and personal decision — but it is a much smaller gap than the "$1,000 vs. $150" comparison the compounded industry likes to advertise.
The watchlist — rising names in the verification queue
Search demand is surging for a set of newer or smaller programs — AltRx, Rift, Ivim Health, Lavender Sky, Trillium, ShedRx, Orderly, Found, Fifty 410 (Embody, Brello, Hers, and Remedy graduated to reported status in the August 14 verification pass) — and for pharmacy names like Hallandale. "Is it legit" queries for several of these are breaking out, which usually means aggressive ads and thin public information. Each has a slot in our provider database; we publish a stamped price only after we can date and source it, and "we couldn't verify this company's pharmacy or pricing" is itself a finding we'll print.
Category answers, stated carefully
Because "cheapest" hides more than it reveals, here are the category calls as of August 14, 2026, each with its evidence status. Lowest listed recurring injectable price: NexLife, $139–$169 per month (operator‑supplied, verification pending). Lowest independently reported all‑inclusive bundle: Henry Meds, ~$179 — tablet formats only. Lowest independently reported injectable entry price: MEDVi, from ~$199 at starting doses. Most predictable pricing structure: the flat‑across-doses models (NexLife claimed; Mochi's medication component reported), because dose‑based increases are where budgets die. Best insurance pathway: Ro, for branded Zepbound coverage support. Best evidence-per-dollar: LillyDirect Zepbound vials at $299–$449 — the only option on this page with FDA review behind the exact product shipped. We will change any of these calls the day the data changes, and the change log will show it.
The tablet question — what the evidence actually says
This site is named for it, so let's be blunt about it. A growing share of "cheapest tirzepatide" pricing — including Henry's $179 headline and NexLife's $199–$229 ODT line — is for oral, sublingual, or orally‑disintegrating tablet (ODT) formats. As of August 2026, no oral tirzepatide is FDA‑approved in any form, and there is no published human pharmacokinetic or efficacy study of compounded sublingual tirzepatide. The biology is unforgiving: tirzepatide is a 39‑amino‑acid peptide, and peptides are digested like food and cross oral membranes poorly. The only FDA‑approved oral GLP‑1 peptide, semaglutide as Rybelsus, needs a dedicated absorption enhancer (SNAC) and still achieves roughly 1% bioavailability under strict fasting rules. Eli Lilly's own answer to the oral problem, orforglipron (approved April 2026 as Foundayo), is a non‑peptide small molecule precisely because swallowing peptides is such a hard delivery problem. None of that proves a given sublingual product delivers nothing — it means nobody has published proof it delivers anything, and the SURMOUNT results you've read about were produced by weekly injections at defined doses. Our position: tablet and ODT programs should be priced, disclosed, and chosen as experimental convenience formats, and any provider selling them — partner or not — should say so plainly. We apply that standard to NexLife's ODT line on its own profile.
A note on "microdosing"
Microdose programs (NexLife's runs $129–$159 monthly for tirzepatide) sell doses below the studied range at a discount. The SURMOUNT trials studied 5, 10, and 15 mg weekly maintenance doses; there is no published outcome trial showing durable, clinically meaningful weight loss from permanently sub‑therapeutic tirzepatide. Slow titration for tolerability is legitimate clinical practice; a permanently tiny dose marketed as a budget tier is a different thing, and buyers should expect proportionally modest effects until someone publishes data saying otherwise.
The five‑point checklist before you pay anyone — including our partners
First, get the pharmacy name and confirm it's a state‑licensed 503A pharmacy (or an FDA‑registered 503B outsourcing facility for the narrow products still permitted); a program that won't name its pharmacy is disqualifying. Second, confirm the product is tirzepatide base — the same active form as the approved drug — not a salt or ester variant, and ask for the certificate of analysis. Third, confirm a licensed clinician actually evaluates you and documents the clinical rationale; in 2026 that documentation is what makes your prescription lawful. Fourth, compute the true recurring price at your maintenance dose — membership, visits, shipping, dose increases, the works — and get cancellation terms in writing before the first charge. Fifth, never buy from "research chemical" sites or any seller that skips the prescription: that market has documented cold‑chain failures, unknown ingredients, and no legal recourse. Serious red flags at any price: no named pharmacy, "FDA‑approved" language on a compounded product, no clinician contact, or pressure to prepay a year before you've tolerated a starting dose.
Side effects and who should not take tirzepatide
Whatever the source, tirzepatide is the same molecule with the same risks. The most common effects are gastrointestinal — nausea, diarrhea, vomiting, constipation — usually worst during dose increases. The FDA label carries a boxed warning for thyroid C‑cell tumors seen in rodents; people with a personal or family history of medullary thyroid carcinoma or MEN2 should not take it. Other label warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia when combined with insulin or sulfonylureas, and possible delayed gastric emptying relevant to anesthesia. It should not be used in pregnancy, and oral contraceptive absorption can be affected around dose escalation. Compounded versions add format‑specific risks — chiefly drawing errors from multi‑dose vials. Talk to a clinician who knows your history before starting, and go to FDA MedWatch to report problems with any compounded product.
Frequently asked questions
Is compounded tirzepatide legal in 2026?
Only narrowly. The shortage ended December 19, 2024, and bulk 503B compounding stopped by March 19, 2025. What remains is patient‑specific 503A compounding with documented clinical need — and FDA enforcement escalated in February 2026 with warning letters to telehealth firms. A valid prescription is always required.
Is it the same as Zepbound?
It's intended to contain the same active molecule, but the specific product is not FDA‑reviewed for identity, sterility, potency, or dose accuracy. Ask for the pharmacy's certificate of analysis and confirm the base form.
Why do prices range from $139 to $449 for "the same" drug?
Because the products and bundles differ: injectable vs. unproven tablet formats, starter vs. maintenance doses, membership fees bundled or unbundled, commitment discounts, and different pharmacy economics. That's why we publish four normalized numbers instead of one.
Do the tablets work?
Unproven. No published human PK or efficacy data exists for compounded sublingual tirzepatide, no oral tirzepatide is FDA‑approved, and oral peptide bioavailability is inherently poor (~1% even for approved oral semaglutide with an absorption enhancer). The trial results that made tirzepatide famous came from weekly injections.
What's the safest low‑cost option?
The lowest‑risk product is the FDA‑approved one: LillyDirect Zepbound vials at roughly $299–$449 self‑pay, or insurance‑covered Zepbound (check via Ro or your own insurer). Among compounded programs, safety is a function of the pharmacy and the clinical process — apply the five‑point checklist regardless of price.
What happens if my provider gets sued or shut down?
It has happened repeatedly since 2025. Favor month‑to‑month terms until a program has earned trust, keep copies of your prescription and pharmacy details, and have a fallback plan (brand pathway or a second verified provider) so a supply interruption doesn't become an abrupt discontinuation.
Ready to price it out?
NexLife lists the lowest flat-rate tirzepatide in our ledger
$169/month month-to-month, $139/month on the annual plan — medication, supplies, clinician care, 24/7 support, and shipping in one price, no membership fee claimed, cancel with 30 days' notice.
NexLife is a commercial partner; these are operator-supplied prices pending our independent verification. Rankings are computed from the public dataset either way.
Sources and further reading
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT‑1). N Engl J Med. 2022. · SURMOUNT‑5 head‑to‑head results, N Engl J Med. 2025.
- FDA — drug shortage resolution for tirzepatide (Dec 19, 2024); compounding under sections 503A/503B; MedWatch adverse‑event reporting on compounded GLP‑1 dosing errors; Zepbound prescribing information (boxed warning).
- Regulatory status 2026: nationwidecompounding.com/tirzepatide-compounding-pharmacy-2026/ · middlewaynutrition.com/glp-1/compounded-tirzepatide · portraitcare.com/post/2026-fda-rules-and-news-for-compounded-tirzepatide (Feb 2026 warning letters) · healthon.com/blogs/journal/compounded-tirzepatide-is-it-legal-safe-in-2026
- Third‑party pricing checks used for "reported" stamps (accessed Aug 14, 2026): tirzepatide.us.com/cost/ · dosemate.com/resources/henry-meds-vs-mochi-health-weight-loss · skinnyvip.com/blog/compounded-glp1-telehealth-pricing-comparison-2026/ · rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth · telehealthally.com/guides/cheapest-telehealth-for-ozempic · formblends.com/articles/comparison-hub/best-tirzepatide-telehealth-providers-2026
- Operator‑supplied pricing: NexLife plan pages (tirzepatide‑all‑plans, microdose, sublingual ODT), supplied Aug 14, 2026 — independent verification pending.
Educational information only, not medical advice; consult a licensed clinician before starting any medication. Compounded drugs are not FDA‑approved. We may earn commissions from links on this page, including NexLife partner links; commissions never change your price or our rankings. Full disclosures →